France attaches strings to Acomplia reimbursements

France has agreed to partial reimbursement for the cost of Sanofi-Aventis' obesity drug Acomplia, but has placed some severe restrictions in its guidelines. The country will pay 35 percent of the cost of the drug, provided the patient is obese, has type 2 diabetes and meets certain blood sugar levels. In addition, only patients who have failed standard diabetic therapies and diet and exercise programs are covered. In France, drugs are partially reimbursed by the government, with employers covering all or a large part of the remaining bill.

- check out this article from the Acomplia Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.